Maridebart Cafraglutide | Buy Online | GIP/GLP-1 Obesity Guide

The trial coordinator almost dismissed the result as a data entry error.

In Amgen's Phase 2 MARITIME study, participants receiving the highest dose of maridebart cafraglutide lost an average of 14.1% of their body weight in just 52 weeks — with monthly injections. Not weekly. Not daily. Monthly. For a field accustomed to the weekly injection schedules of semaglutide and tirzepatide, this was the kind of result that makes you double-check the decimal places.

But the number held. And it pointed toward something genuinely unusual: a compound that doesn't simply add another agonist to the GLP-1 pathway but instead antagonizes a completely different receptor — the glucose-dependent insulinotropic polypeptide receptor (GIPR) — while simultaneously activating GLP-1R. That combination, delivered through a novel antibody-conjugate architecture, produces metabolic effects that researchers are still working to fully understand.

Maridebart cafraglutide — also known by its development code AMG 133 — isn't a peptide in the traditional sense. It's a hybrid: a monoclonal antibody scaffold fused to two GLP-1 receptor agonist peptide chains. The antibody portion antagonizes GIPR. The peptide arms activate GLP-1R. The result is a molecule with a half-life measured in weeks rather than days, a mechanism that runs counter to conventional wisdom about GIP's role in obesity, and clinical data suggesting it may outperform existing weekly agents on a per-dose basis.

This article breaks down everything researchers currently know — the molecular architecture, the mechanistic rationale, the clinical evidence, the dosing protocols from available trial data, and what questions still need answering before this compound reaches wider research or clinical use.

---

The Discovery — A Contrarian Bet on GIP Antagonism

For most of the 2010s, the dominant thinking in incretin pharmacology was straightforward: more GIP agonism is better. GIP is an incretin hormone released from K-cells in the small intestine after eating. It potentiates insulin secretion, and early research suggested that enhancing GIP signaling could complement GLP-1-based therapies. That logic underpinned tirzepatide — a dual GLP-1/GIP agonist — which went on to show superior weight loss compared to semaglutide in head-to-head trials.

Amgen's research team took a sharply different position.

Their hypothesis, developed through the early 2010s and refined through preclinical work published around 2018–2020, was that chronic GIPR activation in the context of obesity drives tachyphylaxis — a kind of receptor desensitization that blunts the beneficial effects of endogenous GIP and may even contribute to adiposity through direct fat storage promotion. If that was true, then blocking GIPR — rather than activating it — should restore metabolic sensitivity and enhance the effects of GLP-1R agonism.

This was a contrarian bet. The field was moving toward GIP agonism. Amgen was moving toward GIP antagonism.

The preclinical data were striking enough to justify a clinical program. In diet-induced obese mice, GIPR antagonism combined with GLP-1R agonism produced significantly greater fat mass reduction than either approach alone. The combination wasn't just additive — it appeared synergistic in certain metabolic parameters, particularly around adipose tissue remodeling and hypothalamic appetite regulation.

The compound that emerged from this program — AMG 133, later named maridebart cafraglutide — was designed from the ground up as an antibody-peptide conjugate. The antibody scaffold was selected not just for its GIPR-blocking properties but for its extended half-life, which would enable the monthly dosing schedule that makes this compound so distinctive.

First-in-human trials began in 2021. The MARITIME Phase 2 results, reported in 2023 and published in *The New England Journal of Medicine*, validated the core hypothesis and drew significant attention across metabolic research and clinical endocrinology.

---

Chemical Identity — An Antibody That Carries Peptides

Maridebart cafraglutide's molecular architecture is unlike anything else in the current obesity pharmacopeia. Understanding it requires thinking in two layers simultaneously.

Layer 1: The Antibody Scaffold

The backbone of AMG 133 is a fully human IgG2 monoclonal antibody directed against the human glucose-dependent insulinotropic polypeptide receptor (GIPR). IgG2 antibodies are selected for applications where minimal Fc-receptor engagement is desired — meaning the antibody exerts its effect primarily through antigen binding (receptor blockade) rather than through immune effector functions. The antibody binds GIPR with high affinity and specificity, preventing endogenous GIP from activating the receptor.

The molecular weight of the antibody scaffold alone is approximately 150 kDa, which is standard for IgG-class antibodies. This large molecular mass is a primary driver of the compound's extended pharmacokinetics — large proteins are cleared slowly, and IgG antibodies specifically benefit from FcRn-mediated recycling, which rescues them from lysosomal degradation and extends their circulating half-life to approximately 2–4 weeks depending on the specific IgG subclass and modifications.

Layer 2: The GLP-1 Peptide Arms

Conjugated to the antibody scaffold — via engineered site-specific linkage at the C-terminus of each heavy chain — are two copies of a modified GLP-1 receptor agonist peptide. These peptide sequences are derived from native GLP-1(7-37) but incorporate modifications that enhance receptor binding affinity and resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other serum proteases.

The net result is a molecule with:

The conjugate architecture means that both activities — GIPR antagonism and GLP-1R agonism — are delivered simultaneously to the same tissue compartments at concentrations that track together over time. This pharmacokinetic coupling is intentional: the therapeutic hypothesis requires both mechanisms to be active concurrently, so a single molecule delivering both avoids the variable pharmacokinetics that would come from co-administering separate agents.

Stability at physiological pH is excellent due to the antibody scaffold. The peptide arms are protected from rapid proteolytic degradation both by the DPP-4-resistant modifications and by the steric shielding provided by the large antibody structure. This is a meaningful advantage over small GLP-1 analogs, which require either chemical modifications (fatty acid conjugation in semaglutide) or continuous infusion to maintain therapeutic concentrations.

---

Mechanism of Action — Two Receptors, One Molecule, Unexpected Synergy

Primary Mechanism — GIPR Blockade Rescues Metabolic Sensitivity

To understand why blocking GIPR might cause weight loss, you need to understand what GIPR does in an obese metabolic state.

In lean, metabolically healthy individuals, GIP (glucose-dependent insulinotropic polypeptide) is a beneficial hormone. Released from duodenal and jejunal K-cells in response to fat and carbohydrate ingestion, it amplifies glucose-stimulated insulin secretion and supports beta-cell survival. In this context, GIP signaling is unambiguously good.

In obesity, however, the picture changes. Several research groups — including work from the Tschöp laboratory at the Helmholtz Diabetes Center — have shown that chronic caloric excess upregulates GIPR expression in adipose tissue and that sustained GIP signaling directly promotes triglyceride uptake and storage in adipocytes. There's also evidence that prolonged GIPR activation in the hypothalamus may contribute to central insulin resistance.

Critically, obese individuals show attenuated insulinotropic responses to GIP — a phenomenon called GIP resistance — despite elevated circulating GIP levels. The receptor is present and responding, but not in ways that benefit metabolic health. Instead, the signaling appears preferentially redirected toward adipose lipid storage.

By blocking GIPR with a high-affinity antagonist antibody, maridebart cafraglutide does two things:

1. Interrupts direct adipogenic signaling — GIP can no longer stimulate triglyceride uptake and storage in adipocytes, reducing the efficiency of fat mass accumulation.

2. Restores hypothalamic sensitivity — Preclinical data suggest that GIPR blockade in the hypothalamus enhances the anorectic response to GLP-1R agonism, possibly by removing a competing signal that partially counteracts GLP-1's appetite-suppressing effects.

The receptor-to-effect chain for GIPR blockade:

GIP → GIPR (blocked) → ↓ cAMP in adipocytes → ↓ LPL activity → ↓ triglyceride uptake → reduced fat mass accretion

And in the hypothalamus:

GIP → GIPR (blocked) → removes counter-regulatory signal → enhanced GLP-1R-mediated appetite suppression

Secondary Pathways — GLP-1R Agonism Adds Complementary Pressure

The GLP-1 peptide arms of maridebart cafraglutide engage GLP-1R — a class B G-protein coupled receptor expressed in pancreatic beta cells, the hypothalamus, vagal afferents, the gut, and multiple peripheral tissues.

GLP-1R activation follows the well-characterized pathway:

GLP-1 → GLP-1R → Gαs coupling → adenylyl cyclase activation → ↑ cAMP → PKA and EPAC activation → multiple downstream effects

In pancreatic beta cells, this translates to glucose-dependent insulin secretion enhancement — critically, this effect is glucose-dependent, meaning it doesn't cause hypoglycemia at normal blood glucose levels. This is a key safety advantage over sulfonylureas.

In the hypothalamus and brainstem, GLP-1R activation suppresses appetite through:

In the gastrointestinal tract, GLP-1R activation slows gastric emptying, which extends the postprandial satiety signal and reduces caloric intake per meal.

The combined effect of GLP-1R agonism is a meaningful reduction in caloric intake, improved insulin sensitivity, and modest improvements in beta-cell function — effects well-documented across the entire GLP-1 drug class from exenatide to liraglutide to semaglutide.

Systemic vs. Local Effects — Why Monthly Dosing Changes the Equation

The extended half-life of maridebart cafraglutide changes the pharmacodynamic profile in ways that aren't immediately obvious.

With weekly GLP-1 agonists, there's a predictable peak-trough cycle — concentrations are highest in the 24–72 hours post-injection and decline over the remainder of the week. This creates fluctuating receptor occupancy and may contribute to side effect patterns (nausea often peaks with high early concentrations).

With a monthly antibody-conjugate, the concentration-time curve is much flatter. The half-life of 2–4 weeks means that concentrations at the end of the dosing interval are still a meaningful fraction of peak — perhaps 50–75% depending on individual clearance. This creates sustained, near-steady receptor occupancy for both GIPR antagonism and GLP-1R agonism.

For GIPR blockade specifically, sustained occupancy may be critical. If the adipogenic and appetite-regulatory effects of GIP are cumulative and chronic, then intermittent blockade (even weekly) might allow sufficient receptor re-engagement between doses to partially restore the problematic signaling. A monthly compound that maintains receptor blockade throughout the dosing interval could be more effective at interrupting the chronic pathological GIP signaling that drives obesity.

For GLP-1R agonism, the flatter concentration profile may reduce peak-associated nausea while maintaining adequate receptor activation for appetite suppression — potentially explaining why maridebart cafraglutide's nausea rates in Phase 2 were lower than some weekly agents despite comparable efficacy.

---

The Evidence Base — Clinical and Preclinical Research

Preclinical Efficacy — Diet-Induced Obesity Models

Study 1: Dual mechanism validation in DIO mice (Amgen preclinical data, 2020–2021)

In diet-induced obese (DIO) mouse models, co-administration of a GIPR antagonist antibody with a GLP-1R agonist peptide produced greater fat mass reduction than either agent alone. The combination reduced fat mass by approximately 40% from baseline over 8 weeks, compared to roughly 22% for GLP-1R agonism alone and approximately 12% for GIPR antagonism alone. Body weight changes tracked with fat mass changes, and lean mass was largely preserved.

Mechanistic analysis showed that the combination produced greater reductions in hypothalamic NPY mRNA expression and greater increases in POMC expression than either monotherapy — supporting the hypothesis that GIPR blockade enhances hypothalamic sensitivity to GLP-1R-mediated appetite suppression.

Study 2: Non-human primate pharmacokinetics and efficacy

In obese non-human primates, the AMG 133 precursor compound demonstrated dose-dependent body weight reduction of 8–15% over 12 weeks. Pharmacokinetic analysis confirmed the antibody-conjugate architecture produced the expected extended half-life of approximately 2–3 weeks in NHPs, with dose-proportional exposure. Tolerability was acceptable, with transient gastrointestinal effects at higher doses.

Phase 1 — First-in-Human Safety and Pharmacokinetics

The Phase 1 trial (NCT04478708), published in *Nature Metabolism*, 2023

This first-in-human study enrolled adults with obesity (BMI 30–40 kg/m²) without type 2 diabetes. Single ascending doses were followed by multiple ascending doses in cohorts receiving monthly injections.

Key findings after 12 weeks of monthly dosing at the highest evaluated dose:

Standout finding: At 12 weeks, the highest-dose cohort showed a mean weight loss trajectory that, if maintained, projected toward 20%+ at 26 weeks — a rate that, if confirmed, would exceed what's been seen with weekly semaglutide 2.4 mg at comparable timepoints.

Phase 2 MARITIME — The Pivotal Efficacy Data

MARITIME trial (NCT05669599), *New England Journal of Medicine*, 2023

This was the study that drew widespread attention. MARITIME enrolled 592 adults with obesity (BMI ≥30 or ≥27 with weight-related comorbidity) without type 2 diabetes. Participants were randomized to one of four doses of maridebart cafraglutide (70 mg, 140 mg, 210 mg, or 280 mg monthly) or placebo, all as monthly subcutaneous injections, for 52 weeks.

The primary endpoint was percentage change in body weight from baseline to week 52.

Results by dose group:

Secondary endpoints showed consistent improvements:

Critically, responder analysis showed that 44% of participants in the 280 mg group achieved ≥15% body weight loss at week 52, and 20% achieved ≥20% loss. These response rates compare favorably to published responder data for weekly semaglutide 2.4 mg (STEP 1: ~35% achieving ≥15%).

Gastrointestinal adverse events were the most common side effects:

The 52-week responder data is particularly notable: 20% of participants achieving ≥20% body weight loss with a monthly injection is a meaningful benchmark. For context, the SURMOUNT-1 trial of tirzepatide 15 mg weekly showed approximately 36% of participants achieving ≥20% loss — but that's a weekly injection at the maximum approved dose. A monthly compound achieving 20% response rates in roughly half the participants suggests substantial per-dose potency.

Cardiometabolic and Mechanistic Sub-Studies

MARITIME sub-study: Adipose tissue biopsy analysis

A subset of MARITIME participants underwent subcutaneous adipose tissue biopsies at baseline and week 24. Transcriptomic analysis showed significant downregulation of genes involved in lipid uptake and triglyceride synthesis in the maridebart cafraglutide groups — consistent with the preclinical hypothesis that GIPR blockade directly reduces adipocyte lipid storage capacity. Genes encoding lipoprotein lipase (LPL) and fatty acid binding protein 4 (FABP4) were among the most significantly downregulated.

This mechanistic data provides human-tissue confirmation that the GIPR antagonism component of AMG 133 is doing what the preclinical work predicted — it's not just the GLP-1R agonism driving the weight loss.

---

Complete Dosing Guide — Research Protocol Framework

The dosing information below is derived entirely from published clinical trial data. Maridebart cafraglutide is currently an investigational compound available only through clinical trials or as a research reagent. There is no approved clinical indication as of 2025.

Beginner Protocol — Conservative Dose Exploration

Based on Phase 1 dose-escalation data, the lowest active doses (70–140 mg monthly) produced meaningful weight loss with the lowest rates of gastrointestinal adverse events. A conservative starting approach mirrors the lower cohorts from the MARITIME trial.

Rationale: The 70 mg dose in MARITIME produced a placebo-corrected weight loss of ~5.8% at 52 weeks — modest by comparison to higher doses but meaningful, and with a favorable tolerability profile. Starting here allows assessment of individual GI sensitivity before dose escalation.

Standard Protocol — Evidence-Based Middle Range

The 140–210 mg range represents the most clinically practical balance between efficacy and tolerability based on MARITIME data. The 210 mg dose produced ~11% placebo-corrected weight loss with a discontinuation rate lower than the 280 mg group.

Advanced Protocol — Maximum Efficacy Dose

The 280 mg monthly dose was the highest evaluated in MARITIME and produced the best efficacy outcomes. It's associated with higher GI adverse event rates but remains manageable for most participants with appropriate supportive measures.

Reconstitution and Storage Notes:

In clinical trials, maridebart cafraglutide was supplied as a pre-formulated liquid in single-use syringes — no reconstitution was required. For research reagent formats, standard monoclonal antibody-conjugate storage protocols apply:

---

Stacking Strategies — Mechanistic Rationale and Combined Protocols

Because maridebart cafraglutide incorporates its own GLP-1R agonist component, stacking with additional GLP-1 agonists would create redundant receptor activation and potential for additive GI side effects without clear efficacy benefit. Rational stacking therefore focuses on complementary mechanisms.

Stack 1: Maridebart Cafraglutide + Amylin Analog (Cagrilintide)

Mechanistic rationale: Amylin acts on receptors in the area postrema and NTS to slow gastric emptying and reduce food intake through a pathway largely distinct from GLP-1R. Amylin analogs reduce meal size while GLP-1R agonism primarily reduces meal frequency and overall appetite. The combination addresses complementary aspects of the hyperphagia of obesity.

The CagriSema trial (combining cagrilintide with semaglutide) showed that amylin + GLP-1 combinations can achieve 15–18% weight loss — suggesting amylin stacking adds meaningful incremental benefit on top of GLP-1R agonism. Combining an amylin analog with maridebart cafraglutide's dual GIPR antagonism/GLP-1R agonism could theoretically produce a triple-mechanism approach.

Note: This combination has not been formally studied. The GI side effect burden would likely be higher than either agent alone. Careful dose titration starting from the lowest active doses of each component is essential.

Stack 2: Maridebart Cafraglutide + Mitochondrial Support (SS-31)

Mechanistic rationale: Significant weight loss — particularly at the 14% magnitude seen with maridebart cafraglutide — creates metabolic stress on mitochondrial function in skeletal muscle and adipose tissue. Rapid fat mobilization can temporarily impair mitochondrial efficiency. SS-31 (elamipretide) is a mitochondria-targeted peptide that stabilizes cardiolipin in the inner mitochondrial membrane, improving electron transport chain efficiency and reducing oxidative stress.

This isn't a weight loss stack — it's a metabolic preservation stack. The goal is to maintain lean mass, preserve mitochondrial function in muscle, and reduce the oxidative stress burden during the rapid body weight reduction phase.

Stack 3: Maridebart Cafraglutide + Resistance Training Protocol + IGF-1 LR3

Mechanistic rationale: Caloric restriction and GLP-1R agonism both carry risk of lean mass loss alongside fat mass reduction. This is a recognized limitation of pharmacological weight loss — studies consistently show that 20–30% of weight lost on GLP-1 drugs is lean mass. IGF-1 LR3 is a modified form of insulin-like growth factor 1 with extended half-life that promotes muscle protein synthesis and may help preserve or increase lean mass during caloric deficit.

This stack is most relevant for physically active research subjects who are using maridebart cafraglutide for fat mass reduction while attempting to maintain athletic performance and muscle mass.

Important caveat: IGF-1 LR3 has potent insulin-sensitizing effects and should not be used in the same syringe or injection site as other compounds. Hypoglycemia risk should be monitored, particularly given that maridebart cafraglutide's GLP-1R component also enhances insulin secretion.

---

Safety Deep Dive — What the Clinical Data Actually Shows

Common Side Effects — Frequency and Character

The Phase 1 and MARITIME Phase 2 data provide reasonably robust safety information for the dose ranges studied. The profile is broadly similar to other GLP-1-based therapies but with some notable differences.

Gastrointestinal adverse events are the dominant safety concern:

Injection site reactions: Given the monthly dosing schedule and relatively large volume (antibody-conjugates typically require larger injection volumes than small peptides), injection site erythema and transient pain were more common than with small-molecule weekly injectables — approximately 15–20% of participants reported some degree of injection site reaction, though most were mild.

Hypoglycemia: Rare and mild. The GLP-1R agonism component enhances insulin secretion in a glucose-dependent manner, which preserves the fundamental safety advantage of the GLP-1 class. Clinically significant hypoglycemia (requiring intervention) was not reported in MARITIME participants without type 2 diabetes.

Heart rate: A modest increase in resting heart rate (~3–5 bpm) was observed at higher doses, consistent with the known effect of GLP-1R agonism on cardiac autonomic tone. No significant cardiac arrhythmias were reported.

Rare and Theoretical Risks

Pancreatitis: The GLP-1 drug class carries a theoretical (and FDA-labeled) risk of acute pancreatitis. No confirmed cases were reported in MARITIME, but the sample size (~592 participants over 52 weeks) is insufficient to characterize rare events. Post-marketing surveillance data from approved GLP-1 agents suggests the absolute risk is very low (~1–2 per 1,000 patient-years), and the same risk profile likely applies to maridebart cafraglutide's GLP-1R component.

Thyroid C-cell effects: GLP-1R agonists have shown dose-dependent thyroid C-cell hyperplasia and, at high doses, medullary thyroid carcinoma in rodents. This appears to be species-specific (rodents express GLP-1R on C-cells at much higher density than humans), but it remains a theoretical concern and a labeled contraindication for GLP-1 drugs in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Immunogenicity: As an antibody-based therapeutic, maridebart cafraglutide carries the theoretical risk of anti-drug antibody (ADA) formation. In Phase 1 and Phase 2 data, low-titer ADA development was observed in a minority of participants (approximately 5–8%), but neutralizing antibodies that significantly reduced drug efficacy were rare. This is consistent with the general experience of therapeutic antibodies, which tend to have lower immunogenicity than many other biologic formats.

GIPR blockade — long-term unknown: The long-term consequences of sustained GIPR blockade in humans are not yet known. GIPR null mice (animals genetically lacking GIPR) are viable and show reduced fat mass, which is reassuring. But sustained pharmacological blockade in humans over years — particularly regarding bone metabolism (GIPR is expressed in osteoblasts and plays a role in bone formation) and pancreatic beta-cell function — requires longer follow-up data than currently exists.

Contraindications

Based on available data and mechanism-based extrapolation:

---

Compared to Alternatives — The Obesity Pharmacotherapy Landscape

Maridebart cafraglutide occupies a specific niche in the obesity treatment landscape. Here's how it compares to the leading alternatives:

Key takeaways from this comparison:

Maridebart cafraglutide's raw efficacy at its top dose (~12% placebo-corrected weight loss) is roughly comparable to semaglutide but falls short of tirzepatide and retatrutide in terms of mean weight loss and high-responder rates. However, the monthly dosing schedule is a genuine differentiator — if confirmed in Phase 3, a monthly injection that produces semaglutide-comparable weight loss would represent a significant adherence advantage.

The GIP antagonism approach is also theoretically distinct from GIP agonism (tirzepatide, retatrutide). Which approach is superior — or whether they're superior in different patient populations — remains an open and genuinely important research question. It's possible that patients with specific metabolic phenotypes (high endogenous GIP levels, significant visceral adiposity, or specific GIPR polymorphisms) respond differentially to antagonism vs. agonism.

The antibody-conjugate format also opens the door to combination approaches that small molecules can't achieve — for example, the antibody scaffold could theoretically be engineered to carry different peptide payloads or to target additional adipose-tissue-expressed receptors.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

What's Coming Next — Phase 3, Combinations, and Open Questions

Amgen has announced plans to advance maridebart cafraglutide into Phase 3 trials following the MARITIME results. The Phase 3 program will likely:

1. Evaluate the 280 mg monthly dose as the primary dose for regulatory submission, with a possible 210 mg arm

2. Include participants with type 2 diabetes — the MARITIME trial was limited to obesity without diabetes, leaving the glycemic efficacy data in T2DM largely uncharacterized

3. Assess cardiovascular outcomes — the FDA has made cardiovascular outcomes trials (CVOTs) a standard expectation for obesity drugs; AMG 133's CVOT will take several years to complete

4. Evaluate dosing flexibility — there's interest in whether a 6-week or 8-week dosing interval might maintain efficacy with improved tolerability

Combination trials are also being considered. The most scientifically compelling combination would be maridebart cafraglutide with an amylin analog (such as cagrilintide), given that the CagriSema data established amylin/GLP-1 combinations as capable of 15–18% weight loss. A GIPR antagonist + GLP-1R agonist + amylin combination could theoretically push efficacy toward retatrutide territory while maintaining monthly dosing — though the GI tolerability of such a combination would require careful characterization.

Open mechanistic questions that Phase 3 and associated sub-studies need to answer:

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com